Amine Boualem
@benzdi80.bsky.social
M.D. GP/Primary Care Physician. East Anglia, UK. Interests: Internal Medicine, Diabetes care, Lipidology & Preventive Cardiology.
Vamos Carlos! Gracias!
June 8, 2025 at 7:01 PM
Vamos Carlos! Gracias!
A fascinating history of Hans Christian Hagedorn and the invention of his NPH insulin. Erik Hageman, one of the longest-living diabetics in Denmark, was fortunate to cross paths with Dr Hagedorn.
May 4, 2025 at 5:28 PM
A fascinating history of Hans Christian Hagedorn and the invention of his NPH insulin. Erik Hageman, one of the longest-living diabetics in Denmark, was fortunate to cross paths with Dr Hagedorn.
The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma - The Lancet www.thelancet.com/journals/lan...
The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma
Coronary artery disease has long been understood through the paradigm of epicardial
coronary artery obstruction, causing myocardial ischaemia (a mismatch between myocardial
blood supply and demand). H...
www.thelancet.com
April 4, 2025 at 11:03 PM
The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma - The Lancet www.thelancet.com/journals/lan...
February 7, 2025 at 11:22 PM
Reposted by Amine Boualem
Atrial fibrillation (AF) is associated with increased rates of stroke, heart failure, and mortality.
This narrative review examines the epidemiology, pathophysiology, diagnosis, and treatment of AF.
➡️ ja.ma/3PP0yrY
#MedSky
This narrative review examines the epidemiology, pathophysiology, diagnosis, and treatment of AF.
➡️ ja.ma/3PP0yrY
#MedSky
January 28, 2025 at 8:42 PM
Atrial fibrillation (AF) is associated with increased rates of stroke, heart failure, and mortality.
This narrative review examines the epidemiology, pathophysiology, diagnosis, and treatment of AF.
➡️ ja.ma/3PP0yrY
#MedSky
This narrative review examines the epidemiology, pathophysiology, diagnosis, and treatment of AF.
➡️ ja.ma/3PP0yrY
#MedSky
Reposted by Amine Boualem
⚠️ The FDA has approved Ozempic for use in kidney disease. #nephrology #nephsky #kidneydisease #diabetes #ozempic #semaglutide
FDA Approves Ozempic for Kidney Disease | Docwire News
Based on FLOW trial results, the FDA has approved Ozempic (semaglutide) to treat chronic kidney disease (CKD) in adults with type 2 diabetes.
buff.ly
January 28, 2025 at 9:21 PM
⚠️ The FDA has approved Ozempic for use in kidney disease. #nephrology #nephsky #kidneydisease #diabetes #ozempic #semaglutide
Pooled prospective cohort studies have observed a J- or U-shaped curve between HDL-C, cardiovascular risk and overall mortality[7,8]
Romero-Jiménez, Manuel Jesús. 2025. HDL and cardiovascular risk. Atherosclerosis 400: doi: 10.1016/j.atherosclerosis.2024.119050. doi.org/10.1016/j.at...
Romero-Jiménez, Manuel Jesús. 2025. HDL and cardiovascular risk. Atherosclerosis 400: doi: 10.1016/j.atherosclerosis.2024.119050. doi.org/10.1016/j.at...
Redirecting
doi.org
January 13, 2025 at 11:49 AM
Pooled prospective cohort studies have observed a J- or U-shaped curve between HDL-C, cardiovascular risk and overall mortality[7,8]
Romero-Jiménez, Manuel Jesús. 2025. HDL and cardiovascular risk. Atherosclerosis 400: doi: 10.1016/j.atherosclerosis.2024.119050. doi.org/10.1016/j.at...
Romero-Jiménez, Manuel Jesús. 2025. HDL and cardiovascular risk. Atherosclerosis 400: doi: 10.1016/j.atherosclerosis.2024.119050. doi.org/10.1016/j.at...
@drlipid.bsky.social
I found a new book on lipidology but, the title is puzzling.
I found a new book on lipidology but, the title is puzzling.
January 7, 2025 at 12:59 PM
@drlipid.bsky.social
I found a new book on lipidology but, the title is puzzling.
I found a new book on lipidology but, the title is puzzling.
Reposted by Amine Boualem
Is It Primetime for Finerenone in Heart Failure?
www.ahajournals.org/doi/abs/10.1...
@ahajournals.bsky.social
#Cardiosky #Medsky #Cardiology #HeartFailure #Finerenone
www.ahajournals.org/doi/abs/10.1...
@ahajournals.bsky.social
#Cardiosky #Medsky #Cardiology #HeartFailure #Finerenone
January 5, 2025 at 3:48 AM
Is It Primetime for Finerenone in Heart Failure?
www.ahajournals.org/doi/abs/10.1...
@ahajournals.bsky.social
#Cardiosky #Medsky #Cardiology #HeartFailure #Finerenone
www.ahajournals.org/doi/abs/10.1...
@ahajournals.bsky.social
#Cardiosky #Medsky #Cardiology #HeartFailure #Finerenone
Reposted by Amine Boualem
More on Lipid/Lipoprotein History: This manuscript, authored by John Gofman team at the Donner Lab in the American Journal of Medicine in 1954 was supposedly the first time the term HYPERLIPOPROTEINEMIA appeared in the literature www.amjmed.com/article/0002-9343(54)90126-6/abstract
January 5, 2025 at 2:05 PM
More on Lipid/Lipoprotein History: This manuscript, authored by John Gofman team at the Donner Lab in the American Journal of Medicine in 1954 was supposedly the first time the term HYPERLIPOPROTEINEMIA appeared in the literature www.amjmed.com/article/0002-9343(54)90126-6/abstract
Reposted by Amine Boualem
Welcome to our Bluesky page! We are excited to share our most recent article: Lipidology: The Time is Now for Specialty Recognition. Read it at www.lipidjournal.com/article/S193...
#openaccess #journal #NLA
#openaccess #journal #NLA
Lipidology: The Time is Now for Specialty Recognition
On May 2, 2024, the National Lipid Association (NLA) submitted its request to the
National Uniform Claim Committee for a new Health Care Provider Taxonomy code for
“Lipidology,”1 which, if endorsed, w...
www.lipidjournal.com
December 3, 2024 at 6:38 PM
Welcome to our Bluesky page! We are excited to share our most recent article: Lipidology: The Time is Now for Specialty Recognition. Read it at www.lipidjournal.com/article/S193...
#openaccess #journal #NLA
#openaccess #journal #NLA
Reposted by Amine Boualem
Efficacy of Mineralocorticoid Receptor Antagonists on Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: An Umbrella Review
https://buff.ly/3VQUN09
https://buff.ly/3VQUN09
December 21, 2024 at 8:08 PM
Efficacy of Mineralocorticoid Receptor Antagonists on Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: An Umbrella Review
https://buff.ly/3VQUN09
https://buff.ly/3VQUN09